GAP-134 structure
|
Common Name | GAP-134 | ||
|---|---|---|---|---|
| CAS Number | 943134-39-2 | Molecular Weight | 291.30200 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C14H17N3O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of GAP-134Danegaptide (GAP-134), a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability. |
| Name | (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid |
|---|---|
| Synonym | More Synonyms |
| Description | Danegaptide (GAP-134), a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability. |
|---|---|
| Related Catalog | |
| Target |
Gap junction. |
| In Vitro | Gap junction uncoupling can alter conduction pathways and promote cardiac re-entry mechanisms that potentiate many supraventricular arrhythmias, such as atrial fibrillation (AF) and atrial flutter (AFL). Gap junction modifier Danegaptide (GAP-134), showed consistent efficacy on measures of conduction and AF/AFL inducibility in the canine sterile pericarditis model. Danegaptide (GAP-134) is a pharmalogical agent with a favorable clinical safety profile and potential antiarrhythmic efficacy, as already confirmed in phase I clinical trials. |
| References |
| Molecular Formula | C14H17N3O4 |
|---|---|
| Molecular Weight | 291.30200 |
| Exact Mass | 291.12200 |
| PSA | 116.22000 |
| LogP | 0.64220 |
| Storage condition | 2-8℃ |
|
~%
GAP-134 CAS#:943134-39-2 |
| Literature: Bioorganic and Medicinal Chemistry Letters, , vol. 19, # 16 p. 4551 - 4554 |
|
~%
GAP-134 CAS#:943134-39-2 |
| Literature: US2007/149460 A1, ; Page/Page column 33-34 ; US 20070149460 A1 |
| zp1609 |
| danegaptide |
| gap-134 |
| unii-pa0y7735at |